Enlivex Therapeutics Ltd.
ENLV
$1.00
-$0.01-0.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.66% | 16.62% | 43.09% | 56.36% | 54.42% |
| Total Depreciation and Amortization | -46.88% | -52.13% | -82.00% | -24.77% | -24.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.42% | -296.04% | -85.19% | 82.21% | -41.40% |
| Change in Net Operating Assets | -69.82% | 51.14% | -34.15% | -260.72% | 140.31% |
| Cash from Operations | 33.33% | -2.53% | 22.61% | 51.88% | 74.41% |
| Capital Expenditure | 56.25% | 25.58% | -400.00% | 68.97% | 57.89% |
| Sale of Property, Plant, and Equipment | 24,300.00% | 50.00% | 480.39% | -- | -98.78% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 206.80% | -41.65% | -24.30% | -109.21% | 71.63% |
| Cash from Investing | 234.63% | -37.76% | -18.79% | -64.59% | 70.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -62.41% | 1,146.41% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -62.50% | 62.50% | -322.22% | -- | -89.47% |
| Cash from Financing | -100.00% | -62.40% | -- | -- | 10,421.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.06% | -212.77% | 146.85% | 35.07% | 118.88% |